Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

252.86 -5.52 (-2.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings this Tuesday after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
Where Jazz Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. ↗
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Preview: Jazz Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching ↗
JAZZ Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and decent growth, making it a candidate for value investors. Check the full analysis for details. 
Via Chartmill
News headline image
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz ↗
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options 
Via Benzinga
News headline image
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching ↗
JAZZ Pharmaceuticals (NASDAQ:JAZZ) is an undervalued biopharma stock with strong profitability, reasonable financial health, and steady growth, making it a candidate for value investors. 
Via Chartmill
News headline image
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study ↗
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients. 
Via Benzinga
News headline image
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and reasonable growth, making it a potential pick for value investors. 
Via Chartmill
News headline image
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s... 
Via StockStory
Topics World Trade
News headline image
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Jazz Pharmaceuticals (NASDAQ:JAZZ) Misses Q1 Sales Targets
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s... 
Via StockStory
News headline image
Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q1 Results Tomorrow
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results tomorrow after market close. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow afternoon. Here’s what to look for. 
Via StockStory
News headline image
Despite its impressive fundamentals,JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) remains undervalued. ↗
When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock ↗
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock 
Via Chartmill
News headline image
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
Jazz Pharmaceuticals currently trades at $109.85 per share and has shown little upside over the past six months, posting a small loss of 1.4%. 
Via StockStory
News headline image
3 Small-Cap Stocks in the Doghouse
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Where Jazz Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
3 Value Stocks Skating on Thin Ice
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals. ↗
JAZZ PHARMACEUTICALS PLC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:JAZZ showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.